Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2012 by BioMarin Pharmaceutical.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
BioMarin Pharmaceutical
ClinicalTrials.gov Identifier:
NCT01230801
First received: October 27, 2010
Last updated: September 20, 2012
Last verified: September 2012
  Purpose

A Phase 1/2, open-label, multicenter, multiple dose escalation study of BMN 701 administered by intravenous infusion every 2 weeks over a 24-week treatment period to patients with late-onset Pompe disease.


Condition Intervention Phase
Pompe Disease
Biological: BMN 701
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1/2 Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic and Preliminary Efficacy of BMN 701 (GILT-tagged Recombinant Human GAA) in Patients With Late-onset Pompe Disease

Resource links provided by NLM:


Further study details as provided by BioMarin Pharmaceutical:

Primary Outcome Measures:
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Anti-BMN 701 antibody titer [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Anti-Insulin-like-growth-factor antibody titer [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetic profile of BMN 701 [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Mean distance walked as measured by the Six-minute Walk Test (6MWT) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: December 2010
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BMN 701
IV infusion
Biological: BMN 701
GILT-tagged recombinant human GAA

  Eligibility

Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Patient or patient's parent or legal guardian has provided written informed consent after the nature of the study has been explained, and prior to any study-related procedures;
  • Patient has been diagnosed with Pompe Disease prior to or during the screening period based on 2 GAA gene mutations and either: endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed in cultured skin fibroblasts -or- endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed by dried blood spot or whole blood assay;
  • Patient is male or female and 13 years of age or older at the time of enrollment in the study;
  • Sexually active patients must be willing to use an acceptable method of contraception while participating in the study and for at least 30 days following the last dose of BMN 701;
  • If patient is female and not considered to be of childbearing potential, she is at least 2 years post-menopausal or had tubal ligation at least 1 year prior to screening, or who have had total hysterectomy;
  • If patient is female and of childbearing potential, she has negative urine pregnancy tests during the Screening Period and at the Baseline visit and be willing to have additional pregnancy tests during the study;
  • Patient has ≥30% predicted upright FVC and either <80% predicted upright FVC, or >10% reduction in supine FVC compared to upright FVC during the Screening Period;
  • Patient is naïve to Enzyme Replacement Therapy (ERT) with rhGAA;
  • Patient must be able to ambulate at least 40 meters (131.2 feet) on the 6MWT conducted at the Screening visit (use of assistive devices such as walker, cane, or crutches, is permitted); and
  • Patient has the ability to comply with the protocol requirements, in the opinion of the Investigator.

Exclusion criteria:

  • Patient has a history of diabetes or other disease known to cause hypoglycemia and is currently receiving, or might anticipate receiving, hypoglycemic agents during the course of the study;
  • Patient has been on any immunosuppressive medication other than glucocorticosteroids within 1 year prior to enrollment into this study;
  • Patient requires invasive ventilatory assistance at the time of enrollment into the study;
  • Patient has received any investigational medication within 30 days prior to the first dose of study drug or is scheduled to receive any investigational drug other than BMN 701 during the course of the study;
  • Patient has previously been admitted to the study;
  • Patient is breastfeeding at screening or planning to become pregnant (self or partner) at any time during the study;
  • Patient has a medical condition or extenuating circumstance that, in the opinion of the Investigator, might compromise the patient's ability to comply with the protocol requirements or compromise the patient's well being or safety;
  • Patient has any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01230801

Locations
United States, California
Univ of California San Diego School of Medicine
La Jolla, California, United States, 92103-8765
UCLA Neurological Services
Los Angles, California, United States, 90095
United States, Florida
University of Florida College of Medicine
Gainesville, Florida, United States, 32610
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
France
Hôpital de I´Archet- Centre Hospitalier Universitaire Nice
Nice, France, 06202
Hôpital Pitié-Salpêtrière
Paris, France, 75013
Germany
Zentrum für Kinder- und Jugenmedizin
Mainz, Rheinland-pfalz, Germany, 55131
United Kingdom
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom, B15 2TH
Royal Free Hospital
London, United Kingdom, NW3 2QG
Salford Royal Hospital NHS Trust
Salford, United Kingdom, M6 8HD
Sponsors and Collaborators
BioMarin Pharmaceutical
Investigators
Study Director: William Lang, MD BioMarin Pharmaceutical
  More Information

No publications provided

Responsible Party: BioMarin Pharmaceutical
ClinicalTrials.gov Identifier: NCT01230801     History of Changes
Other Study ID Numbers: POM-001, 2010-023561-22
Study First Received: October 27, 2010
Last Updated: September 20, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Brain Diseases, Metabolic, Inborn
Glycogen Storage Disease Type II
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Glycogen Storage Disease
Carbohydrate Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on September 18, 2014